GenMark Diagnostics, Inc
GNMK
GNMK was delisted on the 21st of April, 2021.
163 hedge funds and large institutions have $987M invested in GenMark Diagnostics, Inc in 2020 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 52 increasing their positions, 56 reducing their positions, and 20 closing their positions.
75% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 20
10% more funds holding
Funds holding: 148 → 163 (+15)
1.06% more ownership
Funds ownership: 96.78% → 97.85% (+1.1%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1% less capital invested
Capital invested by funds: $1,000M → $987M (-$12.5M)
7% less repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 56
73% less call options, than puts
Call options by funds: $1.63M | Put options by funds: $6.01M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$20.9M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$12.1M |
| 3 |
AC
Armistice Capital
New York
|
+$12.1M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$10.7M |
| 5 |
Morgan Stanley
New York
|
+$10M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$24.4M |
| 2 |
Millennium Management
New York
|
-$18.5M |
| 3 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$11.8M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$11M |
| 5 |
O
OrbiMed
New York
|
-$10.8M |
GNMK Hedge Fund Activity: Q3 2020 in Review
163 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in GenMark Diagnostics, Inc (GNMK) for Q3 2020, worth a combined $987M — down 1.2% from $1,000M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new GNMK positions and 20 closed out — a net gain of 15 holders — while 52 added to existing stakes and 56 trimmed.
The largest buyer was Macquarie Group, adding an estimated $20.9M. The largest seller was Consonance Capital Management, cutting an estimated $24.4M.
- 163 institutional investors held GenMark Diagnostics, Inc (GNMK) as of Q3 2020, up from 148 in Q2 2020.
- Funds reported $987M of GenMark Diagnostics, Inc stock for Q3 2020, down 1.2% quarter-over-quarter.
- 35 funds opened new GenMark Diagnostics, Inc positions in Q3 2020 and 20 closed out, a net change of +15 holders.
- The largest GenMark Diagnostics, Inc buyer in Q3 2020 was Macquarie Group, an estimated $20.9M added.
- The largest GenMark Diagnostics, Inc seller in Q3 2020 was Consonance Capital Management, an estimated $24.4M sold.
Based on aggregated 13F filings for Q3 2020.